The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Designing Paclitaxel Drug Delivery Systems Aimed at Improved Patient Outcomes: Current Status and Challenges
Open accessAbstract
Paclitaxel is one of the most widely used and effective antineoplastic agents derived from natural sources. It has a wide spectrum of antitumor activity, particularly against ovarian cancer, breast cancer, nonsmall cell lung cancer, head and neck tumors, Kaposi's sarcoma, and urologic malignancies. It is a highly lipophilic compound with a log P value of 3.96 and very poor aqueous solubility of less than 0.01 mg/mL. In addition, the compound lacks functional groups that are ionizable which could potentially lead to an increase in its solubility with the alteration in pH. Therefore, the delivery of paclitaxel is associated with substantial challenges. Until the introduction of Abraxane, only commercial formulation was solution of paclitaxel in cremophor, which caused severe side effects. However, in recent years, a number of approaches have been reported to solubilize paclitaxel using cosolvents and inclusion complexes. In addition, innovative approaches have been reported for passive targeting of tumors using nanoparticles, nanosuspensions, liposomes, emulsions, micelles, implants, pastes and gels. All approaches for delivery of improved therapeutic outcome have been discussed in this paper.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924
In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy
Kim, S. C., Kim, D. W., Shim, Y. H., Bang, J. S., Oh, H. S., Kim, S. W., & Seo, M. H. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00275-9 · Cited by 734
High affinity binding of paclitaxel to human serum albumin
Paál, K., Müller, J., & Hegedûs, L. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.02107.x · Cited by 191
Cited by
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come
Yingchoncharoen, P., Kalinowski, D. S., & Richardson, D. R. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012070 · Cited by 744
Saari, H., Lázaro-Ibáñez, E., Viitala, T., Vuorimaa-Laukkanen, E., Siljander, P., & Yliperttula, M. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.09.031 · Cited by 613
Liposomal Drug Delivery Systems and Anticancer Drugs
Olusanya, T., Haj Ahmad, R., Ibegbu, D., Smith, J., & Elkordy, A. (2018) · Molecules · doi:10.3390/molecules23040907 · Cited by 603
Rabbani, G., & Ahn, S. N. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.11.053 · Cited by 505
Oral lipid nanomedicines: Current status and future perspectives in cancer treatment
El Moukhtari, S. H., Rodríguez-Nogales, C., & Blanco-Prieto, M. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.004 · Cited by 70
Wang, S., Attah, R., Li, J., Chen, Y., & Chen, R. (2018) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.8b01040 · Cited by 29
A review on Stimuli-pH responsive liposomal formulation in cancer therapy
Jayapriya, P., Pardhi, E., Vasave, R., Guru, S. K., Madan, J., & Mehra, N. K. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105172 · Cited by 24
Metadata
- Authors
- Surapaneni, M. S., Das, S. K., & Das, N. G.
- Venue
- ISRN Pharmacology
- Publisher
- Wiley
- Published
- 2012-08-12
- Volume
- 2012
- Pages
- 1-15
- ISSN
- 2090-5165 (ISSN-L)
- 2090-5173
- OpenAlex
- W2054253814
- Cited by
- 179
- References
- 3
- FWCI
- 3.49
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.